Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd.
Date:9/5/2008

XI'AN, China, Sept. 5 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB) (the "Company"), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production in Xi'an, China, is pleased to announce a Letter of Intent to enter into a contractual arrangement with Xi'an Qinba Xintong Medical Ltd. ("Qinba"). Under the proposed terms of this arrangement, Huifeng will take over operational control of Qinba and will receive a management fee equal to all of Qinba's profit.

"As a manufacturer of finished medical devices, Qinba will give Huifeng immediate access to pharmacy and medicine buyers," stated Huifeng's CEO and founder Jing'An Wang. "With this Letter of Intent, Huifeng has taken the first step toward positioning itself for synergistic growth beyond its core revenue base."

Mr. Wang further noted that Huifeng is now commencing a vertical integration strategy intended to transform the company from a producer of raw materials for the Traditional Chinese Medicine industry to a full-scale pharmaceutical company supplying end products to consumers worldwide.

"With this Letter of Intent, we have proven our ability to attract accretive deals within the People's Republic of China," continued Mr. Wang. "Moving forward, we hope to close on several larger strategic partnerships."

Huifeng is maintaining its guidance for $18M in revenue and $4M of net income.

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties in Xi'an China. Fo
'/>"/>

SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
4. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
5. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
6. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
7. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
8. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
9. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
10. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
11. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ISTANBUL , May 21, 2013 ...  European Dialysis and Transplant Association) is the biggest congress ... renal replacement therapy. Nearly 10,000 participants are in ... discuss the latest research findings. New pioneering studies have ... al. "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ...
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Revolutionary Science, ... automatic colony counter, announced today that they have expanded ... products , the IncuCount, IntelliCount, InCount and ImpressCount. ... sophistication are especially useful in food microbiology and pharmaceutical ... an updated look. A bright white enclosure with ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2
... Inc. (Nasdaq:,EVVV) will release its 2008 second quarter and ... market trading hours., The company will host a ... Central Time (8:30 a.m. Eastern Time). ev3 management will ... by a,question and answer session., The conference call ...
... an Attractive Domestic Alternative to High Priced ... Fulcrum BioEnergy, Inc.,today announced that it is ... build one of the first commercial-scale production,facilities ... The plant will,process municipal solid waste-household garbage ...
... environmental technology,company SEKAB has signed an agreement for ... LDC Bioenergia, a Brazilian ethanol,and sugar industry leader ... "The agreement safeguards supplies of additional volumes ... environmental and social,sustainability," says Anders Fredriksson, Executive Vice ...
Cached Biology Technology:ev3 Inc. to Report 2008 Second Quarter Financial Results and Host Conference Call on August 1, 2008 2Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 2Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 3SEKAB Agreement: More Verified Ethanol to Europe 2
(Date:5/20/2013)... Foundation (NSF) planning grant will help establish the Center ... of the University of Illinois at Urbana-Champaign and Worcester ... be devoted to research in drying moist, porous materials ... paper products; chemical products; textiles; and biopharmaceuticals," said Hao ... and human nutrition and the Illinois site director. , ...
(Date:5/20/2013)... at the University of Bristol and published online today ... light on how the brain and inner ear developed ... of Earth Sciences, together with Tom Hbner from the ... 150 million year old dinosaurs. , The two palaeontologists ... lettowvorbecki : a very young (juvenile) individual of ...
(Date:5/19/2013)... reports that white men and women of European descent ... and lesser toe deformities, including hammer or claw toe. ... the heritability of foot disorders in humansappear in ... Wiley on behalf of the American College of Rheumatology ... as 60% of older adults have foot disorders which ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2Blame your parents for bunion woes 2
... more common in areas of mountaintop coal mining and ... common, according to a study by researchers at Washington ... led by Melissa Ahern, health economist and associate professor ... per 10,000 births where mountaintop mining is most common ...
... 23, 2011 (Bethesda, MD): Today, on behalf of the ... public comments at the US Food and Drug Administration,s ... Diagnostic Applications Approaches to Assess Analytical Validity." As ... diagnostics, AMP advised FDA officials on many important considerations ...
... will promote fish stock recovery and increase fishermen,s incomes, according ... In the North Sea up to 75 per cent of ... that many fisheries are now badly overfished. In comparison, discards ... their fisheries are now some of the most prosperous in ...
Cached Biology News:Large numbers of birth defects seen near mountaintop mining operations 2AMP comments at FDA meeting on next-generation sequencing 2Discards ban 'will boost fisheries', says new research 2
sodium channel, nonvoltage-gated 1 alpha,...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 9 ... tubes. Box dimensions: 13 x 13 x ...
Biology Products: